ABSTRACT
INTRODUCTION
Due to an ageing population, percutaneous coronary intervention (PCI) is being increasingly undertaken in patients with multiple comorbidities and complex lesions. device is a percutaneous catheter-based impeller-driven LVAD which aspirates blood from the LV cavity expelling the removed blood into the aorta. It has been shown to provide superior cardiac support compared with IABP in both animal [9, 10] and human studies [11] , reducing LV end diastolic pressure, wall stress, myocardial oxygen consumption and improving coronary perfusion and cardiac output [12] [13] [14] .
As a result, PCI is increasingly performed in
The Impella device has gained increasing popularity in acute cardiac care, most commonly in high-risk PCI. Large registries [16] . In addition to high-risk PCI, Impella has also been used successfully in cardiogenic shock [17] [18] [19] [20] , acute cardiac transplant rejection [21, 22] and refractory heart failure as a bridge to transplantation [23, 24] . Historically, IABP has been the mechanical assist device of choice in the UK, although recent trials from the UK have shown no early benefit of prophylactic IABP in elective highrisk PCI [5] , with a recent analysis showing a beneficial effect on 5-year mortality [25] . We therefore, present our experience with the use of the Impella device in a UK quaternary cardiac centre.
METHODS
The Queen Elizabeth Hospital, Birmingham, UK, is a large quaternary cardiac centre and provides regional cardiac transplantation. We retrospectively analysed our interventional procedural database and identified all patients undergoing Impella implantation since the start of the programme in October 2008 until January 2014 on an intention to treat basis. Clinical and procedural data was procured from electronic patient records, the procedural database and procedure logs in the cardiac catheter laboratory. All patients were included in an intention to treat manner; there were no exclusions.
The 2.5L and 3.8L Impella devices were inserted via the femoral approach. The 5L Impella was inserted via the subclavian artery following surgical exposure and application of a Dacron graft, as previously described [26] A Judkins right or Amplatz catheter was used to cross the aortic valve following which the 0.018 00 Impella guide wire was positioned in the aortic apex. The Impella device was then positioned carefully in the LV apex over the 0.018 00 wire and set to maximal output. Special manoeuvres were required for insertion of the device in the five patients who had concomitant severe aortic stenosis (AS), as described recently by our group [27] .
Outcome data for mortality was obtained from electronic patient records linked to the Office of National Statistics database. Periprocedural myocardial infarction (PMI) was defined as a total creatinine kinase level greater than three times the upper limit of normal on the morning after the procedure [28, 29] . Data are presented as mean ± standard deviation (SD) for continuous variables and percentages for discrete variables.
The analysis in this article is based on previously conducted data, and does not involve any new studies of human or animal subjects performed by any of the authors.
RESULTS
Impella implantation was attempted in a total of 49 patients during the study period: of these, 45 patients underwent high-risk PCI, 3 patients required emergency haemodynamic support as a bridge to cardiac transplantation and one patient with severe AS underwent balloon valvuloplasty (BAV) with Impella support.
Implantation of a 2.5L Impella failed in one patient undergoing high-risk PCI due to extreme calcific iliofemoral disease.
Implantation was successful in 48 (98%) patients. Of these, the 2.5L Impella device was used in 36 (75%) patients, the 3.8L device in 11 (23%) patients, and the 5L device in one patient (2%).
The baseline clinical characteristics of these patients are shown in Table 1 patients were given the 13F 3.8L device, while 34 patients were given the 12F 2.5L device.
Impella was removed following PCI before the patient left the catheter laboratory in all but two patients and in these patients, successful vascular closure was achieved with pre-closure use of one or two ProGlide devices. PCI was performed via the radial approach in 11 patients (25%) and the femoral approach in 33 (75%). The peri-procedural variables are shown in Table 2 .
The majority of patients (80%) had severe LV impairment (LVEF \35%) with 53% (24/45) of patients undergoing PCI to an unprotected left main stem. Five patients had severe AS with coronary artery disease and PCI was performed in preparation for transcatheter aortic valve replacement (TAVR) or balloon valvuloplasty for clinical stabilisation.
PCI was performed electively in 17 (38%) patients: 11 of these patients were discussed at a heart multi-disciplinary team (MDT) meeting and were thought to be at higher risk for CABG. 
Impella for Balloon Aortic Valvuloplasty
One patient with severe AS and intractable cardiogenic shock underwent successful bailout balloon valvuloplasty with Impella (3.8L)
support. The patient tolerated the procedure well with a favourable haemodynamic response. However, he had a suspected retroperitoneal haematoma which prompted removal of the device. Shortly afterwards, the patient succumbed to pulmonary oedema and cardiogenic shock.
Impella as a Bridge to Transplant
Three patients had Impella as a bridge to cardiac transplantation. Two of these patients had acute cardiogenic shock following ST-elevated myocardial infarction (STEMI), despite successful primary angioplasty and conventional management including IABP.
One patient had a 2.5L Impella implanted via the femoral approach, which allowed sufficient haemodynamic recovery and made the patient suitable for transplantation with an excellent outcome. The other patient had a 5L Impella (21F) inserted via surgical subclavian access, but unfortunately, passed away due to gastrointestinal bleeding and multiple organ system failure-complications unrelated to Impella.
The third patient with acute decompensated heart (and renal) failure due to dilated cardiomyopathy had a 2.5L Impella implanted femorally but needed early extracorporeal membrane oxygenation (ECMO) due to insufficient haemodynamic response; he eventually underwent successful cardiac and renal transplantation.
Outcomes
The 30-day outcomes are shown in Table 3 . Inhospital death occurred in 10 patients (20%).
One patient in whom Impella could not be implanted due to vessel tortuosity underwent high-risk PCI but died due to ischaemic cardiogenic shock immediately following the procedure. Two further patients in this group died due to cardiogenic shock, while one died of pre-existing severe sepsis, having also had a stroke with a dense neurodeficit in the setting of significant bilateral carotid artery stenoses. Two The Impella ventricular assist device (VAD) system, however, has been shown to provide superior haemodynamic support than IABP [16, by the MDT and were deemed to be at too high risk for CABG due to co-morbidities.
Several risk scoring models such as the Mayo PCI risk score have been developed to anticipate the in-hospital major event rate in PCI. We have used the North West Quality Improvement Programme (NWQIP) scoring system, which had been standardised to a UK population and validated against the established international risk models [31] . Population-based risk models, however, may not capture all the high-risk characteristics of an individual patient, and the definition of high-risk PCI and the need for mechanical LV support remains the discretion of the operator. Indeed our mean NWQIP predicted major event rate was 6 ± 11% (range 0.4-71), which is comparable to the mean Mayo PCI score in the PROTECT II trial (8.8 ± 3.4% in the Impella group) [16] , although our in-hospital mortality was significantly higher at 20%.
The overall 30-day major arrhythmic events (MAE) rate in the USpella registry was 8% with 4% in-hospital mortality [1]. In the Europella registry, 30-day mortality was 5.5% with a 30-day MAE rate of 12.3% (including major vascular complications) [15] . Our in-hospital mortality and MAE of 20% is substantially higher than both these registries. This may either be a reflection of smaller patient numbers in this study, or the higher-risk profile of the population, as discussed earlier. Indeed in the smaller cohort of the Protect I trial (N = 20), the 30-day MAE rate was 20% [32] , while in the larger PROTECT II trial (N = 225) it was 7% [16] .
Interestingly, we report only one major vascular complication in our cohort as compared to 4% in USpella and 5.5% in the Europella registry. While this could be a reflection of smaller patient numbers, it also suggests increasing experience with larger arterial access in the era of percutaneous valvular interventions (TAVI) and the use of newer techniques such as micropuncture and pre-closure with percutaneous suture devices. This is important in a cohort of patients who can ill-afford any further haemodynamic setbacks.
In this cohort, 52% had PCI to unprotected left main stem, 40% underwent multi-vessel PCI and 20% had PCI to the last remaining vesselessentially comparable to the USpella [1] and Europella [15] registries. However, our patients were older (mean age 75 vs. 70 years in the USpella and Europella registries) and had a greater incidence of severe LV impairment (80% vs. 69%). Although the distribution of elective and urgent PCI was comparable to the USpella registry (the Europella registry only included elective cases), we have used Impella in 3 patients with cardiogenic shock, 2 with ischaemic pulmonary oedema and, importantly, in 5 patients with coexisting severe AS; patients with these conditions were not included in the larger registries. Overall, our patients were a substantially higher-risk cohort when compared to these registries. This reflects a growing confidence in the use of Impella and its expanding indications in acute cardiac care.
Impella in Aortic Stenosis
Severe AS is reported to be a contraindication to Impella use due to theoretical concerns of either reducing effective valve orifice or inducing aortic incompetence. However, with increasing experience there have been anecdotal reports [33, 34] and a recent series [35] describing the use of Impella in this setting. The use of Impella in our patients with severe AS is an example of the expanding indication for this device. The methods used for implanting the device in these patients have been described by our group in a previous report [27] . One patient with severe AS and LV dysfunction underwent emergency BAV with Impella support for intractable cardiogenic shock. The rapid deterioration and death that followed removal of the device in this patient for suspected retroperitoneal bleeding highlighted the significant haemodynamic benefit provided by Impella.
Transplantation
Impella was used with success in one patient with acute post-infarct cardiogenic shock as a bridge to transplantation. There are anecdotal reports of the use of Impella in similar situations with both the 2.5L and 5L device, and also in transplanted hearts for acute rejection [21, 22] . A recent series [36] has also reported the use of 5L Impella support in 9 patients with cardiogenic shock due to endstage ischaemic cardiomyopathy (3 patients) and post-ST elevation myocardial infarction (6 patients). This less invasive percutaneous VAD is therefore, a useful additional tool in advanced heart failure management.
We have described the use of the Impella CP 3.8L device in 11 patients-10 for PCI and one BAV. To our knowledge, this is the first series reporting the use of the 3.8L device which has only recently received Conformité Européenne (CE) marking. Notably, despite the larger lumen vascular access (14F vs. 13F for 2.5L), there was no increase in the incidence of vascular complications, and the haemodynamic support was reliable and superior to that provided by the 2.5L device.
We have confirmed that the indications for the Impella device are expanding and that it can be used in acutely unwell patients with a high degree of success. The main limitations of the Impella device include the requirement for large lumen vascular access and closure, and the significantly higher cost of the device as compared to mechanical support using IABP. A recent study has also confirmed costeffectiveness of Impella [37] 
CONCLUSION
We have demonstrated its feasibility and safety in a cohort of higher risk patients with extended and novel indications, and reported for the first time globally the feasibility and safety of the 3.8L device. With increasing experience in the use of Impella, the device may be used to provide invaluable support to increasingly complex patients who would, in turn, have the largest benefit. This could be a subject of future larger studies.
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